GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

HUTCHMED (China) is not owned by hedge funds. Hutchison Whampoa (China) Limited is currently the largest shareholder, with 39% of shares outstanding. In comparison, the second and third largest ...

It is in with the new and out with the old today as the first session of the 119 th U.S. Congress is called to order. Although Republicans will control both the House and Senate for the next two years ...

China National Medical Products Administration (NMPA) has granted acceptance and priority review for the new drug application ...

In separate DLL3 antibody-drug conjugate (ADC) deals, Roche licensed from Innovent Biologics and Ideaya reached for Hengrui.

Hutchmed to divest its 45% equity interest in SHPL to GP Health Service Capital & Shanghai Pharma for approx. US$ 608 million: Hong Kong, Shanghai Friday, January 3, 2025, 13:00 H ...

The firm also announced that it was divesting most of its equity interest in Shanghai Hutchison Pharmaceuticals to invest in its own pipeline.

Share prices were higher during the first trading day of 2025 as investors went on a buying spree late in the session. The benchmark Philippine Stock Exchange index (PSEi) gained 21.60 points to close ...

Hutchmed sells 45% stake in Shanghai venture for $608M, Xgene's pain drug succeeds in Phase 2b, Hookipa buys Poolbeg Pharma, and Capricor gets $10M from Nippon Shinyaku.

In a move designed to advance its pipeline and its “innovative medicines business,” Chinese biotech Hutchmed will ...

Hutchmed China announced a number of advancements on Thursday, including a regulatory milestone for its lung cancer treatment ...

Chinese regulators have accepted HUTCHMED's (HCM) application for priority review for the drug combination Orpathys and ...